Inthe203
7 years ago
ALEXION TRIMMING THE FAT
SEE? I wasn't lying!
They are laying off 50% of their workforce, getting rid of 60% of their compounds, consolidating building and moving to Boston, all to save shareholders money.
This will initially be a HUGE hit to the PPS. We should see a record $70.00 PPS.
However, it really should bounce back immediately up to the $180's in my opinion, as this will become a more leaner company with better profit margins.
Inthe203
8 years ago
CASH IN WHILE IT'S ON A HIGH!
https://seekingalpha.com/news/3273272-alexion-sputtering-kanuma-launch-write-looming
In this seeking alpha article, it clearly indicates where this company is heading. CEO Ludwig Hantson, is notorious for going into Pharmas, trimming the fat and preparing it for a buyout. That executive team that he brought in? They're all a part of the buyout team he formed in the other companies he spearheaded.
As you can see here, he's trimming the fat and I suspect he's getting rid of Alexion's metabolical area which has proven to be disastrous to the company. The article mentions Kanuma being written off, but I suspect that Strensiq will be a part of the deal as well, as both drugs has performed poorly in sales. The didn't include Strensiq as not to alarm the shareholders, but clearly that drug's sales performance is poor as well.
This means Alexion will become a one-hit-wonder again which will result in another wave of massive layoffs which I can only imagine will come before August in my opinion.
I don't even think there's anything else in the company's pipeline that's worthy at this point, is there?
The question is, who's buying them out?
Dr_Thorfin
8 years ago
Quote- "βI have never seen the clinical responses that Iβve observed in IgA nephropathy patients treated with OMS721,β stated Geoffrey Block, M.D., Director of Clinical Research at Denver Nephrology and Principal Investigator of the trial. βAll of these patients had significant renal impairment when they entered the trial and each patient dramatically improved. The improvements in these patients continued to increase after the end of treatment and persisted following completion of the trial. As an active clinical investigator, given the strength of these data, I am working hard to move this promising drug through the clinical trial process.β--